The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Medically reviewed by Jay N. Yepuri, MD Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ...

Counteract sedentary habits by incorporating at least 150 minutes of moderate exercise per week, such as walking, cycling, ...

Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...

Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...

Probiotics may help with many health conditions. Although they're generally safe, it's important to talk with your doctor ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Weight-loss surgery can protect the liver health of patients with obesity and fatty liver disease, a new study repor ...

The FDA approval is based on results from a trial investigating the effects of once-a-week Ozempic injections on major kidney ...

Patients with uncomplicated chronic hypertension who avoid preeclampsia show only marginally higher risk for severe maternal ...

Osmania General Hospital in Hyderabad achieves medical milestone with five liver transplants in 30 days, saving lives of ...